摘要
目的分析多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌患者的临床疗效。方法按照随机平行方法分组,将本院2014年5月至2018年5月的78例晚期卵巢癌患者,分为甲组和乙组。甲组通过多西他赛联合洛铂腹腔灌注化疗,乙组通过多西他赛联合卡铂静脉化疗,对比两组的临床效果。结果甲组和乙组治疗总有效率的数据对比为:84.61%、61.54%,差异有统计学意义(P<0.05)。甲组和乙组的不良反应发生率分别为:33.33%、30.77%,差异无统计学意义。结论多西他赛联合洛铂腹腔灌注治疗晚期卵巢癌,尤其是伴腹水的患者,可达到较好的临床效果,且不会产生严重的不良反应,值得在晚期卵巢癌治疗中应用、推广。
Objective To analyze the clinical efficacy of intraperitoneal infusion of docetaxel plus lobaplatin in the treatment of advanced ovarian cancer.Methods According to the randomized parallel method,78 patients with advanced ovarian cancer were divided into group A and group B.Group A received intraperitoneal chemotherapy with docetaxel plus lobaplatin,and group B received intravenous chemotherapy with docetaxel plus carboplatin.The clinical effects of the two groups were compared.Results The total effective rate of group A and group B was 84.61%and 61.54%.There was statistical significance in two groups(P<0.05).The incidence of adverse reactions in group A and B were 33.33%and 30.77%,respectively.There was no significant difference between the two groups.Conclusion Docetaxel plus lobaplatin intraperitoneal infusion can achieve good clinical effect in the treatment of advanced ovarian cancer,especially in patients with ascites,without serious adverse reactions.It is worthy of application and promotion in the treatment of advanced ovarian cancer.
作者
李言冰
蒋轶
左宏波
王志
Li Yanbing;Jiang Yi;Zuo Hongbo;Wang Zhi(Department of Oncology,Jiujiang First People's Hospital,Jiujiang,Jiangxi,332000,China)
出处
《当代医学》
2019年第1期10-12,共3页
Contemporary Medicine
关键词
多西他赛
洛铂
卡铂
腹腔灌注化疗
晚期卵巢癌
临床疗效
Docetaxel
LPT
Carboplatin
Intraperitoneal chemotherapy
Advanced ovarian cancer
Clinical efficacy
